Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsAfter two failed Alzheimer's trials and a fraud scandal, simufilam is back. The FDA has lifted a clinical hold on the drug, allowing Filana Therapeutics — formerly Cassava Sciences — to launch a Phase 2a study in tuberous sclerosis complex (TSC)-related epilepsy. The 16-week trial will enroll ~40 patients across 13 U.S. sites, with screening expected to begin in Q1 2027.
After a turbulent history marked by data integrity allegations, federal investigations, and two failed Phase 3 Alzheimer's trials, simufilam is getting a fresh start. The FDA has lifted a clinical hold on the drug, clearing Filana Therapeutics — the rebranded successor to Cassava Sciences — to begin a Phase 2a study in tuberous sclerosis complex (TSC)-related epilepsy. The company says it used the hold period productively, engaging a clinical research organization and identifying 13 U.S. trial sites.
The planned study is a 16-week, randomized, double-blind trial with an optional 48-week extension, enrolling approximately 40 patients aged 12–55 with drug-resistant, TSC-related seizures. Primary endpoints include safety, tolerability, pharmacokinetics, and seizure measures. Preclinical support comes from a 2026 Epilepsia study showing simufilam significantly reduced seizure progression in a severe TSC mouse model, with effects correlating to drug dose and plasma exposure.
Key Takeaways:
Why it matters: Drug-resistant epilepsy affects a significant portion of TSC patients, leaving them with few treatment options. While simufilam's past is complicated, its new mechanistic rationale and preclinical data offer a cautious but real reason for hope — and the FDA's clearance signals the science is worth exploring.
